American Cancer Society BrightEdge 2024 Impact Report

American Cancer Society's BrightEdge Impact Venture Fund 2024 annual report detailing investments in 15 oncology portfolio companies spanning diagnostics, therapeutics, and tech-enabled solutions. The report highlights scaling innovations that reached over 400,000 lives in 2024, $3.8 billion in additional funding secured by portfolio companies, and introduction of the proprietary Cancer Impact Investment Framework for industry-standard impact measurement.